Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet agent. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, potentially reducing gastric irritation.
## Primary Indications
* **Cardiovascular Prevention:** Prevention of myocardial infarction (MI), stroke, and cardiovascular death in patients with established cardiovascular disease or risk factors.
* **Analgesia and Anti-inflammatory:** Relief of mild to moderate pain and reduction of inflammation (less common with enteric-coated formulations due to slower absorption).
## Adult Dosing
* **Cardiovascular Prevention:** Typically 75 mg to 150 mg once daily. Dosing may vary based on local guidelines and specific patient risk.
* **Pain and Inflammation:** Doses vary widely. Enteric-coated formulations are generally not preferred for acute pain/inflammation due to delayed absorption. Standard aspirin doses range from 325 mg to 650 mg every 4-6 hours as needed, not to exceed 4000 mg per day.
## Pediatric Dosing
Aspirin is generally **not recommended** for use in children and adolescents due to the risk of Reye's syndrome, especially during viral illnesses.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary in severe renal impairment.
* **Hepatic Impairment:** Use with caution.
## Contraindications
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* Active peptic ulceration or history of recurrent ulceration.
* Bleeding disorders (e.g., hemophilia, von Willebrand disease).
* Severe renal or hepatic impairment.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Concurrent use with methotrexate at anti-inflammatory doses.
* Asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, GI bleeding, ulceration. Enteric coating may reduce but not eliminate this risk.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis, prolonged bleeding from wounds.
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema.
* **Other:** Tinnitus (especially at higher doses), dizziness, headache.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI toxicity.
* **SSRIs/SNRIs:** Increased risk of bleeding.
* **Methotrexate:** Increased methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Decreased efficacy of uricosuric agents.
* **Antihypertensives:** May reduce antihypertensive efficacy.
* **Alcohol:** Increased risk of GI irritation and bleeding.
## Monitoring
* **Signs of GI bleeding:** Melena, hematemesis, abdominal pain.
* **Signs of bleeding:** Easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal function:** Especially in patients with pre-existing renal disease or those taking concurrent nephrotoxic agents.
* **Liver function:** May be considered in patients with hepatic impairment or prolonged high-dose therapy.
* **Tinnitus:** Can be an early sign of salicylate toxicity.
## Clinical Pearls
* Enteric-coated aspirin should be swallowed whole and not crushed, chewed, or broken to maintain the integrity of the coating and prevent premature release.
* Due to delayed absorption, enteric-coated aspirin may not be suitable for rapid pain relief.
* The benefit of low-dose aspirin for cardiovascular prevention must be weighed against the risk of bleeding, particularly in elderly patients or those with a history of GI bleeds.
* Discontinue aspirin at least 5-7 days before elective surgery to minimize bleeding risk.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions. Local protocols may influence dosing and management.*
